Trial Profile
Phase 1 study of PCSK9 mRNA inhibitors
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Antisense oligonucleotides (Primary) ; PCSK9 protein inhibitors (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- 10 Jan 2017 New trial record
- 05 Jan 2017 According to a CiVi Biopharma media release, this trial is expected to start in 2017.